28 December 1998 in FEBS Letters
Human immunodeficiency virus type 1 (HIV‐1) Vif protein is required for productive HIV‐1 infection of peripheral blood lymphocytes and macrophages in cell culture and for pathogenesis in the SCID‐hu mouse model of HIV‐1 infection. Vif inhibits the viral protease (PR)‐dependent autoprocessing of truncated HIV‐1 Gag‐Pol precursors expressed in bacterial cells and efficiently inhibits the PR‐mediated hydrolysis of peptides in cell‐free systems. The obstructive activity of Vif has been assigned to the 92 amino acids residing at its N′‐terminus (N‐Vif). To determine the minimal Vif sequence required to inhibit PR, we synthesized overlapping peptides derived from N‐Vif. These peptides were then assessed, using two in vitro and two in vivo systems: (i) inhibition of purified PR, (ii) binding of PR, (iii) inhibition of the autoprocessing of the Gag‐Pol polyprotein expressed by a vaccinia virus vector, and (iv) inhibition of mature virus production in human cells. The peptides derived from two regions of N‐Vif encompassing residues Tyr‐30–Val‐65 and Asp‐78–Val‐98, inhibited PR activity in both the in vitro and the in vivo assays. Thus, these peptides can be used as lead compounds to design new PR inhibitors.
1 July 2014 in Journal of Molecular Biology
13 October 2015 in The FEBS Journal
SSShivender M. D. Shandilya
Shivender M. D. Shandilya
The cellular cytidine deaminase APOBEC3G (A3G) was first described as an anti‐HIV‐1 restriction factor, acting by directly deaminating reverse transcripts of the viral genome. HIV‐1 Vif neutralizes the activity of A3G, primarily by mediating degradation of A3G to establish effective infection in host target cells. Lymphoma cells, which express high amounts of A3G, can restrict Vif‐deficient HIV‐1. Interestingly, these cells are more stable in the face of treatments that result in double‐stranded DNA damage, such as ionizing radiation and chemotherapies. Previously, we showed that the Vif‐derived peptide (Vif25–39) efficiently inhibits A3G deamination, and increases the sensitivity of lymphoma cells to ionizing radiation. In the current study, we show that additional peptides derived from Vif, A3G, and APOBEC3F, which contain the LYYF motif, inhibit deamination activity. Each residue in the Vif25–39 sequence moderately contributes to the inhibitory effect, whereas replacing a single residue in the LYYF motif completely abrogates inhibition of deamination. Treatment of A3G‐expressing lymphoma cells exposed to ionizing radiation with the new inhibitory peptides reduces double‐strand break repair after irradiation. Incubation of cultured irradiated lymphoma cells with peptides that inhibit double‐strand break repair halts their propagation. These results suggest that A3G may be a potential therapeutic target that is amenable to peptide and peptidomimetic inhibition.
4 May 2017 in Journal of Fish Diseases